Extracorporeal Membrane Oxygenation for Life-Threatening Measles in Children: A Case Series
This retrospective case series demonstrates that extracorporeal membrane oxygenation (ECMO) is a feasible and potentially lifesaving intervention for unvaccinated children with severe measles-induced cardiorespiratory failure, achieving a 60% survival rate despite significant complications from bacterial and fungal coinfections, cardiac dysfunction, and neurologic injury.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Measles is a virus that spreads with terrifying ease, moving from person to person so quickly that a single infected child can spark a large outbreak if enough people around them lack protection. For decades, safe vaccines have kept this disease at bay in many parts of the world, but when vaccination rates drop, the virus returns with a vengeance. While most children recover from measles with rest and supportive care, the infection can sometimes turn deadly. The virus does not just cause a rash and fever; it temporarily shuts down the body's immune defenses, leaving children vulnerable to severe bacterial and fungal infections that follow. In the worst cases, the disease attacks the lungs and the heart, causing them to fail completely. When a child's heart and lungs stop working despite the best efforts of doctors and machines, a last-resort treatment called extracorporeal membrane oxygenation, or ECMO, can step in. This machine acts as an artificial heart and lung, taking blood out of the body, cleaning it, and pumping it back in, giving the child's own organs time to rest and heal.
In a recent study, researchers at a major hospital in Jerusalem examined what happens when children with severe measles reach this critical point. During a large outbreak of the disease between August 2025 and May 2026, the hospital treated dozens of children, but ten of them became so ill that their hearts and lungs could not sustain life without ECMO. All ten children were under the age of eighteen, and none had received the full series of measles vaccines appropriate for their age. The youngest were infants, some only ten months old. The doctors found that these children were fighting a perfect storm of complications. Before their machines were even turned on, half of them already had bacteria in their blood, and nearly all had signs of severe infection in their lungs. The virus had weakened their immune systems so profoundly that their bodies could not fight off these secondary invaders.
Once the children were placed on ECMO, the medical team faced a complex challenge. The machine itself is a powerful tool, but it requires the patient's blood to be thinned to prevent clots, which creates a risk of bleeding. In these specific cases, the children's conditions were further complicated by the fact that their hearts were struggling to pump effectively. In seven of the ten children, the heart's main pumping chamber was weak, and in four cases, the heart was so swollen with blood that doctors had to perform a procedure to relieve the pressure, allowing the heart to function better while the machine did the heavy lifting. The situation was so precarious that the team noticed a disturbing pattern early on: three of the first five children developed a serious fungal infection in their blood. This specific fungus, known as Candida tropicalis, is rare in healthy children but thrives when the immune system is crushed by measles. Recognizing this danger, the doctors changed their approach for the remaining five children, starting them on medication to prevent fungal infections the moment they were connected to the machine. None of these later children developed the fungal infection.
The journey through the intensive care unit was long and difficult. The children stayed on the machines for a median of ten and a half days, with some requiring support for as long as two months. During this time, the medical team also had to watch for damage to the brain, which can occur when the body is in shock or when blood flow is disrupted. Brain scans performed on eight of the children showed serious injuries in four of them, including bleeding, strokes, and swelling. Despite these severe hurdles, the outcome was not hopeless. Six of the ten children, or sixty percent, survived their ordeal and were able to leave the hospital. The two children whose primary problem was breathing failure both survived, while the child whose heart was failing due to suspected viral damage did not make it. The survival rate for the group as a whole matched what doctors see with other life-threatening conditions in children, proving that ECMO is a viable option even for measles, provided the child can be supported through the storm of complications.
The story of these ten children highlights a stark reality. Every single one of them suffered a life-threatening crisis that required the most advanced medical technology available, and every single one of them was unvaccinated. The virus had not only attacked their bodies but had also erased their immune memory, making them easy targets for other deadly infections. The researchers noted that the fungal infections they saw were likely due to the children's own weakened state rather than a mistake in hospital hygiene, suggesting that when a child with measles needs ECMO, doctors should be prepared to treat fungal threats immediately. While the medical team managed to save most of these children, the study serves as a powerful reminder that the greatest tool against this disease is not a machine, but a vaccine. The children who survived did so because of the skill of their doctors and the resilience of their bodies, but the tragedy of their illness began with a gap in community protection that could have been easily filled.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.